Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | NR1D1 | P20393 | 5/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23711054 | 0.96 | CA12 (0.36) | CHRM2TDP1KDM4EALOX15LMNA | |
| SCHEMBL19458 | 0.92 | TDP1 (0.42) | CHRM2TDP1KDM4EALOX15LMNA | |
| SCHEMBL7129262 | 0.91 | TDP1 (0.47) | CHRM2TDP1KDM4EALOX15LMNA | |
| SCHEMBL1433039 | 0.88 | OPRK1 (0.38) | CHRM2KDM4ETSHRNR1D1CA12 | |
| SCHEMBL4335588 | 0.87 | HIF1A (0.35) | CHRM2TDP1KDM4EALOX15LMNA | |
| SCHEMBL7762658 | 0.85 | CHRM2 (0.32) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7567930 | 0.85 | CA12 (0.37) | CHRM2TDP1KDM4EALOX15LMNA | |
| SCHEMBL19661282 | 0.85 | CA1 (0.44) | CHRM2TDP1KDM4EALOX15LMNA | |
| SCHEMBL438113 | 0.85 | TDP1 (0.58) | CHRM2TDP1KDM4EALOX15LMNA | |
| SCHEMBL4621864 | 0.85 | TDP1 (0.58) | CHRM2TDP1KDM4EALOX15LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170119889-A1 | POLYGLUTAMATE-AMINO ACID CONJUGATES AND METHODS | NITTO DENKO CORPORATION (JP) | 2017-05-04 | — | — | US | disclosed |
| US-20020049190-A1 | Pharmaceutical compositions comprising metal complexes | ANORMED INC. (CA) | 2002-04-25 | — | — | US | disclosed |
| EP-1037672-A1 | DENDRITIC POLYMER-SACCHARIDE CONJUGATE, PHARMACEUTICALS CONTAINING SAID CONJUGATE, METHOD FOR ITS PRODUCTION AND USE THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999032154-A1 | DENDRITIC POLYMER-SACCHARIDE CONJUGATE, PHARMACEUTICALS CONTAINING SAID CONJUGATE, METHOD FOR ITS PRODUCTION AND USE THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049190-A1 | Pharmaceutical compositions comprising metal complexes | CFD, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, F12 | CHRM2 187/4885TDP1 3584/4885KDM4E 2866/4885 |
| US-20170119889-A1 | POLYGLUTAMATE-AMINO ACID CONJUGATES AND METHODS | FOLH1, SLC7A1, SLC3A2 | CHRM2 4156/4885TDP1 1214/4885KDM4E 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.